A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 183 participants.
Also called NCT01503736
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 183 participants
- Sponsor
- Registry
-
NCT01503736
-
- Main results
- Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Countries
- Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01503736. Randomized; quadruple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2012-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease
- Condition
- Hyperphosphatemia
- Condition
- End Stage Renal Disease
- Condition
- ESRD
- Intervention (Drug)
- ferric citrate
- Intervention (Drug)
- ferric citrate
- Intervention (Drug)
- ferric citrate
- Lead sponsor
- Panion & BF Biotech Inc.
Record details
- Record id
cardio:ct-nct01503736- Content hash
c09849ffe3bc584954237ede2177628ab0104c5578a5b7c6e8d5526efa8c8412